Both AOD 9604 and tirzepatide have been through human trials, but the depth and outcome of those trials could not be more different
The disease has an autosomal recessive mode of inheritance, and is characterized by excessive copper deposition, predominantly in the liver and brain
The distinction is about mechanism breadth, not potency
That window is validated through stability studies measuring benzyl alcohol concentration, pH drift, and particulate formation over time
I hope they do more research on side effects and how long they last
These effects are why BPC 157 is commonly discussed in relation to tendon injuries, ligament recovery, gut health, wound repair, and inflammation control